Snapshot
The Prioritized Drug Review and Approval Pathway pathway has been developed by the National Medical Products Administration of China.
It is an abridged review (a reliance pathway).
When relevant, the agency relies on prior decisions from EU-EMA United States
The review time limit is 130 days, with 70 days applying to drugs for rare diseases with an urgent clinical need.